This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: University of Central Florida Research Foundation Inc., University of L'aquila. Active years: 2014-2016.
Company Filing History:
2 out of 1,364 
2 out of 2 Years Active: 2014-2016
Title: Annamaria Cimini: Innovator in Alzheimer's Disease Research
Introduction
Annamaria Cimini is a prominent inventor based in L'Aquila, Italy. She has made significant contributions to the field of Alzheimer's disease research through her innovative work on nanoparticles. With a total of two patents to her name, Cimini is dedicated to developing targeted therapies for this challenging condition.
Latest Patents
Cimini's latest patents focus on the use of cerium oxide nanoparticles that are immunologically targeted to an amyloid beta antigen associated with Alzheimer's disease. The first patent discloses a composition containing amine functionalized nanoparticles of cerium oxide, which are coated with polyethylene glycol and bear an antibody specific for the amyloid-beta antigen. This invention also includes a medication manufactured with the targeted nanoceria particles and outlines methods of treatment by administering these particles to patients in need. The second patent mirrors the first, emphasizing the innovative approach to treating Alzheimer's disease through targeted nanotechnology.
Career Highlights
Throughout her career, Annamaria Cimini has worked with esteemed institutions, including the University of Central Florida Research Foundation, Inc. and the University of L'Aquila. Her research has garnered attention for its potential to revolutionize treatment options for Alzheimer's disease.
Collaborations
Cimini has collaborated with notable colleagues, including Barbara D'Angelo and Soumen Das, who have contributed to her research endeavors.
Conclusion
Annamaria Cimini's work in the field of Alzheimer's disease research exemplifies the impact of innovative thinking in medicine. Her patents on cerium oxide nanoparticles represent a promising advancement in targeted therapies for this debilitating condition.